![]() |
BGR Worldwide represents Altimmune, the clinical-stage biopharmaceutical company that is working on a COVID-19 vaccine and a treatment for liver disease triggered by the obesity epidemic.
The publicly traded Gaithersburg, MD-based company last month reported positive results for its single-dose intranasal COVID-19 vaccine candidate that has been under study in collaboration with the University of Alabama at Birmingham.
CEO Vipin Garg announced Sept. 1 that human trials would begin during the fourth-quarter for its treatment for NASH (non-alcoholic fatty liver disease), which is on the rise due to the increase in obesity. Currently, there, there is no treatment for NASH.
BGR founding partner Ed Rogers, a veteran of the Reagan and Bush I White House, leads the Altimmune effort.
Brent Del Monte, co-lead of BGR's science & life sciences group; John Stone, co-lead of the FDA & public health group, and Remy Brim, senior health advisor to Democratic Senators Patty Murray and Elizabeth Warren, round out BGR's Altimmune team.
No comments have been submitted for this story yet.